Generate Biomedicines, Inc.

NASDAQ:GENB

Asset Management

Financial Services
$10.38 +0.91%

+$0.13 today

Market cap
$1.34B
Beta
0.19
P/E (TTM)
-3.5
EPS (TTM)
-$4.06
52W Low $11.00High $16.75

Volume 1.05M

Average 0.55M

GENB Purchases of Investments

Cash used to buy marketable securities and other investments.

Generate Biomedicines, Inc.NASDAQ: GENB

Purchases of Investments · Q1 FY2026 · quarter ended Mar 2026

Purchases of investments of -$321.15M in Q1 FY2026

Q1 FY2026 purchases of investments was -$321.15M.

Context

  • Purchases of investments amounted to 516.5% of revenue in FY2025, down 866.6 pp from a year earlier.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$321.15M— QoQ
Last fiscal yearDec 2025
-$164.73M-41.8% YoY
Purchases of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-41.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Purchases of Investments history

USD · from the cash flow

Latest · FY2025
(164.73M) USD
Year-over-year change
+41.8%

Purchases of Investments vs competitors

How GENB compares with its peers on the latest reported figures

  • GENB's FY2025 purchases of investments of $164.73M is the 3rd largest of the 5 companies compared; the peer median is $172.81M.
  • Its year-over-year change of -41.8% is the 3rd highest of 4, against a peer median of -23.7%.
  • Purchases of investments amounts to 516.5% of revenue for GENB, versus a peer median of 672.6%.
GENB Competitors Peer median
Purchases of Investments for GENB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABCLAbCellera Biologics Inc.LTM Sep 2026$744.36M +50.0%-16.6%1097.0%
STROSutro Biopharma, Inc.LTM Mar 2026$247.27M -47.3%+6.9%248.2%
GENBGenerate Biomedicines, Inc.FY2025$164.73M -41.8%—516.5%
ABSIAbsci CorporationLTM Mar 2026$98.35M -23.7%+3.3%5356.5%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding GENB) $172.81M-23.7%+3.3%672.6%

Competitors are the stored peer set for GENB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD

Generate Biomedicines, Inc.

NASDAQ:GENB

Intrinsic Alpha fair value

Locked

Current Price

$10.38

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.